Triple Negative Breast Cancer Market Size in the 7MM is expected to change during the study period 2019-2032, estimates DelveInsight

“The Triple Negative Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Triple Negative Breast Cancer pipeline products will significantly revolutionize the Triple Negative Breast Cancer market dynamics”

The Triple Negative Breast Cancer market report provides current treatment practices, Triple Negative Breast Cancer emerging drugs, market share of individual therapies, and current and forecasted 7MM Triple Negative Breast Cancer market size from 2019 to 2032. The report also covers current Triple Negative Breast Cancer treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Key Takeaways from the Triple Negative Breast Cancer Market Research Report

• The Triple Negative Breast Cancer market size captured by the United States was found to be the largest among the 7MM countries. It was found that the United States accounted for ~61% of the total market size captured by the 7MM region.
• The leading companies working in the Triple Negative Breast Cancer Market include G1 Therapeutics, AstraZeneca, Daiichi Sankyo, Zenith Epigenetics, Pfizer, OncoSec Medical Incorporated, Merck Sharp & Dohme LLC, Infinity Pharmaceuticals, Roche Pharma AG, OncoPep, and others.
• Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, and others.
• September 2023: Zenith Epigenetics announced a study of phase 2 clinical trials for ZEN003694 and Talazoparib. This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is a dose escalation and Part 2 is a Simon 2-Stage design. There are 3 expansion cohorts: Expansion Cohort A (combination treatment in post-TROP2-ADC patients), Expansion Cohort B (ZEN003694 monotherapy), and Expansion Cohort C (combination treatment in TROP2-ADC-naive patients).
• September 2023: Gilead Sciences announced a study of phase 3 clinical trials for Sacituzumab Govitecan-hziy, Pembrolizumab, and Paclitaxel. The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1). 

Discover more about therapies set to grab major Triple Negative Breast Cancer Market Share @ Triple Negative Breast Cancer Market Size

Triple Negative Breast Cancer Overview

Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of fundamentally different diseases with different histologic, genomic, and immunologic profiles, which are aggregated under this term because of their lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expressions. Massively parallel sequencing and other omics technologies have demonstrated the level of heterogeneity in TNBCs and shed light on the pathogenesis of this therapeutically challenging entity in breast cancer.

Triple Negative Breast Cancer Epidemiology Segmentation in the 7MM

• Total Triple Negative Breast Cancer Incident Cases
• Triple Negative Breast Cancer Subtype-specific Cases
• Triple Negative Breast Cancer Gene Mutation-specific Cases
• Triple Negative Breast Cancer Stage-specific Cases
• Age-specific Cases of Triple Negative Breast Cancer and Line wise Treated Cases

Download the report to understand which factors are driving Triple Negative Breast Cancer Epidemiology Trends @ Triple Negative Breast Cancer Epidemiological Insights

Triple Negative Breast Cancer Marketed Therapies

• LYNPARZA (olaparib)
• TALZENNA (talazoparib)

Triple Negative Breast Cancer Market Outlook

Unlike other forms of breast cancer, TNBC does not respond with hormonal or HER2-targeted treatment. Hence, for a long time, systemic chemotherapy has remained the mainstay treatment for metastatic TNBC. Even for resectable/non-metastatic disease, chemotherapy and surgery in neoadjuvant or adjuvant therapy have been widely used. But the recent approval of various immune checkpoint inhibitors (like pembrolizumab) and targeted therapies (like olaparib and talazoparib) has led to a dynamic shift in the treatment landscape, with their increased usage across various lines of therapy, leading to significant improvement in treatment outcomes and patient prognosis.

Learn more about the Triple Negative Breast Cancer Pipeline Therapies in clinical trials @ Triple Negative Breast Cancer Market Landscape

Scope of the Triple Negative Breast Cancer Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Triple Negative Breast Cancer Companies- G1 Therapeutics, AstraZeneca, Daiichi Sankyo, Zenith Epigenetics, Pfizer, OncoSec Medical Incorporated, Merck Sharp & Dohme LLC, Infinity Pharmaceuticals, Roche Pharma AG, OncoPep, and others.
• Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, and others.
• Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer Market Drivers and Barriers
• Triple Negative Breast Cancer Market Access and Reimbursement, Unmet Needs, and Future Perspectives

Discover more about Triple Negative Breast Cancer Drugs in development @ Triple Negative Breast Cancer Ongoing Clinical Trials Analysis

Table of Content

1. Key Insights

2. Report Introduction

3. Triple Negative Breast Cancer Market Overview at a Glance

4. Triple Negative Breast Cancer Executive Summary

5. Triple Negative Breast Cancer Market Disease Background and Overview

6. Triple Negative Breast Cancer reatment and Management

7. Methodology

8. Epidemiology and Patient Population

9. Patient Journey

10. Triple Negative Breast Cancer Marketed Products

11. Triple Negative Breast Cancer Emerging Therapies

12. Triple Negative Breast Cancer-Seven Major Market Analysis

13. Triple Negative Breast Cancer Market Access and Reimbursement

14. Triple Negative Breast Cancer KOL Views

15. Triple Negative Breast Cancer Unmet Needs

16. Triple Negative Breast Cancer SWOT Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Triple Negative Breast Cancer Market Size in the 7MM is expected to change during the study period 2019-2032, estimates DelveInsight